Pittsburgh Compound-B and Alzheimer's Disease Biomarkers in CSF, Plasma and Urine: An Exploratory Study

被引：30

作者：

Gunnarsson, M. Degerman ^{[1
]}

Lindau, M. ^{[1
,6
]}

Wall, A. ^{[3
]}

Blennow, K. ^{[4
]}

Darreh-Shori, T. ^{[5
]}

Basu, S. ^{[2
]}

Nordberg, A. ^{[5
]}

Larsson, A. ^{[1
]}

Lannfelt, L. ^{[1
]}

Basun, H. ^{[7
]}

Kilander, L. ^{[1
]}

机构：

[1] Uppsala Univ, Dept Publ Hlth Geriatr, Uppsala, Sweden

[2] Uppsala Univ, Dept Publ Hlth Oxidat Stress & Inflammat, Uppsala, Sweden

[3] GE Healthcare Uppsala, Imanet PET Ctr, Uppsala, Sweden

[4] Sahlgrens Univ Hosp, Gothenburg, Sweden

[5] Karolinska Univ Hosp Huddinge, Karolinska Inst, Div Alzheimer Neurobiol, Stockholm, Sweden

[6] Stockholm Univ, Dept Psychol, S-10691 Stockholm, Sweden

[7] BioArctic Neurosci, Stockholm, Sweden

来源：

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS | 2010年 / 29卷 / 03期

关键词：

Pittsburgh Compound-B; PET FDG; Alzheimer's disease; follow-up; Biomarkers; CSF; A beta 1-42; A beta x-42 APOE; Cystatin C; AMYLOID-BETA PROTEIN; CEREBROSPINAL-FLUID; COGNITIVE IMPAIRMENT; TAU-PROTEIN; CYSTATIN-C; WORK GROUP; DEMENTIA; BRAIN; DIAGNOSIS; PREDICTION;

D O I：

10.1159/000281832

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Background: The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PIB) is an in vivo ligand for measuring beta-amyloid (A beta) load. Associations between PET PIB and cerebrospinal fluid (CSF) A beta 1-42 and apolipoprotein E epsilon 4 (APOE epsilon 4) have been observed in several studies, but the relations between PIB uptake and other biomarkers of Alzheimer's disease (AD) are less investigated. Method: PET PIB, PET 18Fluoro-2-deoxy-D-glucose and different AD biomarkers were measured twice in CSF, plasma and urine 12 months apart in 10 patients with a clinical diagnosis of mild to moderate AD. Results: PIB retention was constant over 1 year, inversely related to low CSF A beta 1-42 (p = 0.01) and correlated positively to the numbers of the APOE epsilon 4 allele (0, 1 or 2) (p = 0.02). There was a relation between mean PIB retention and CSF ApoE protein (r = -0.59, p = 0.07), and plasma cystatin C (r = -0.56, p = 0.09). Conclusion: PIB retention is strongly related to CSF A beta 1-42, and to the numbers of the APOE epsilon 4 allele. Copyright (C) 2010 S. Karger AG, Basel

引用

页码：204 / 212

页数：9

共 63 条

[31] Prediction of Alzheimer's disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment [J].

Hansson, Oskar ;

Zetterberg, Henrik ;

Buchhave, Peder ;

Andreasson, Ulf ;

Londos, Elisabet ;

Minthon, Lennart ;

Blennow, Kaj .

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2007, 23 (05) :316-320

[32] Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease [J].

Ikonomovic, Milos D. ;

Klunk, William E. ;

Abrahamson, Eric E. ;

Mathis, Chester A. ;

Price, Julie C. ;

Tsopelas, Nicholas D. ;

Lopresti, Brian J. ;

Ziolko, Scott ;

Bi, Wenzhu ;

Paljug, William R. ;

Debnath, Manik L. ;

Hope, Caroline E. ;

Isanski, Barbara A. ;

Hamilton, Ronald L. ;

DeKosky, Steven T. .

BRAIN, 2008, 131 :1630-1645

[33] Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease [J].

Jesse, Sarah ;

Steinacker, Petra ;

Cepek, Lukas ;

von Arnim, Christine A. F. ;

Tumani, Hayrettin ;

Lehnert, Stefan ;

Kretzschmar, Hans A. ;

Baier, Michael ;

Otto, Markus .

JOURNAL OF ALZHEIMERS DISEASE, 2009, 17 (03) :541-551

[34] PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment [J].

Kemppainen, N. M. ;

Aalto, S. ;

Wilson, I. A. ;

Nagren, K. ;

Helin, S. ;

Bruck, A. ;

Oikonen, V. ;

Kailajarvi, M. ;

Scheinin, M. ;

Viitanen, M. ;

Parkkola, R. ;

Rinne, J. O. .

NEUROLOGY, 2007, 68 (19) :1603-1606

[35] Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B [J].

Klunk, WE ;

Engler, H ;

Nordberg, A ;

Wang, YM ;

Blomqvist, G ;

Holt, DP ;

Bergström, M ;

Savitcheva, I ;

Huang, GF ;

Estrada, S ;

Ausén, B ;

Debnath, ML ;

Barletta, J ;

Price, JC ;

Sandell, J ;

Lopresti, BJ ;

Wall, A ;

Koivisto, P ;

Antoni, G ;

Mathis, CA ;

Långström, B .

ANNALS OF NEUROLOGY, 2004, 55 (03) :306-319

[36] Two-year follow-up of amyloid deposition in patients with Alzheimer's disease [J].

Klunk, William E. ;

Mathis, Chester A. ;

Price, Julie C. ;

Lopresti, Brian J. ;

DeKosky, Steven T. .

BRAIN, 2006, 129 :2805-2807

[37] PET Amyloid Ligand [11C]PIB Uptake and Cerebrospinal Fluid β-Amyloid in Mild Cognitive Impairment [J].

Koivunen, J. ;

Pirttilae, T. ;

Kemppainen, N. ;

Aalto, S. ;

Herukka, S. -K. ;

Jauhianen, A. M. ;

Haenninen, T. ;

Hallikainen, M. ;

Nagren, K. ;

Rinne, J. O. ;

Soininen, H. .

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2008, 26 (04) :378-383

[38] Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P [J].

Koopman, Karen ;

Le Bastard, Nathalie ;

Martin, Jean Jacques ;

Nagels, Guy ;

De Deyn, Peter P. ;

Engelborghs, Sebastiaan .

NEUROCHEMISTRY INTERNATIONAL, 2009, 55 (04) :214-218

[39] Codeposition of cystatin C with amyloid-β protein in the brain of Alzheimer disease patients [J].

Levy, E ;

Sastre, M ;

Kumar, A ;

Gallo, G ;

Piccardo, P ;

Ghetti, B ;

Tagliavini, F .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (01) :94-104

[40]

LEWCZUK P, MOL PSYCHIATR, DOI DOI 10.1038/2008.84

← 1 2 3 4 5 6 7 →